These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36059265)

  • 1. Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease.
    Shiga H; Tarasawa K; Moroi R; Makuuchi M; Takahashi T; Shimoyama Y; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
    J Gastroenterol Hepatol; 2022 Nov; 37(11):2105-2112. PubMed ID: 36059265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.
    Na JE; Park YE; Park J; Kim TO; Lee JH; Park SB; Kim S; Lee SB;
    BMC Gastroenterol; 2024 Sep; 24(1):306. PubMed ID: 39261766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
    Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
    Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
    Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
    Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
    Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
    J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
    Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
    Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
    Eriksson C; Söderling J; Karlqvist S; Bröms G; Everhov ÅH; Bergemalm D; Ludvigsson JF; ; Olén O; Halfvarson J
    Dig Dis Sci; 2023 Jul; 68(7):3119-3128. PubMed ID: 36929241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study.
    Chetwood JD; Ko Y; Pudipeddi A; Kariyawasam V; Paramsothy S; Leong RW
    Am J Gastroenterol; 2024 Aug; 119(8):1536-1544. PubMed ID: 38275272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
    Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
    Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Biologic Therapies in Preventing Penetrating Complications in Patients With Crohn's Disease.
    McCurdy JD; Stwalley D; Olsen MA; Deepak P
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):377-385.e5. PubMed ID: 37673348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent.
    Zhdanava M; Kachroo S; Manceur AM; Ding Z; Holiday C; Zhao R; Godwin B; Pilon D
    Clin Ther; 2023 Aug; 45(8):770-777. PubMed ID: 37442653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
    Rayer C; Nachury M; Bourreille A; Roblin X; Peyrin-Biroulet L; Viennot S; Flamant M; Laharie D; Caron B; Dewitte M; Siproudhis L; Fumery M; Bouguen G
    BMC Gastroenterol; 2022 Dec; 22(1):498. PubMed ID: 36457080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
    Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
    Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
    Am J Gastroenterol; 2022 Jul; 117(7):1106-1117. PubMed ID: 35435862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
    Louis E; Litkiewicz M; Agboton C; Armuzzi A
    United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies.
    Tursi A; Mocci G; Del Gaudio A; Papa A
    Expert Opin Biol Ther; 2024 Mar; 24(3):171-189. PubMed ID: 38321868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.